Becton, Dickinson and Company (BDX) Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
Becton, Dickinson and Company (BDX), headquartered in Franklin Lakes, New Jersey, is a premier player in the healthcare sector, specializing in medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897 and publicly traded since 1972, the company is segmented into three primary divisions: BD Medical, BD Life Sciences, and BD Interventional. This diverse structure allows BDX to cater to a broad spectrum of clients including healthcare institutions, life science researchers, and the pharmaceutical industry. With a solid reputation in the Medical Instruments & Supplies sector, BDX recently received a buy recommendation, indicating positive market sentiment and growth potential.
Stock Performance and Market Sentiment
The current stock price of BDX is $233.50, showing an optimistic target high price of $324.12, implying a substantial upside potential of approximately 38.7%. The target mean price is set at $276.27, suggesting favorable growth expectations aligned with investor sentiments. BDX reported impressive total revenue of $19.83 billion, reflecting strong financial health despite the unavailability of EBITDA data. Analysis of short interest shows that only 0.68% of shares are shorted, indicating minimal bearish sentiment among investors. Given that the stock is trading just below its fifty-day moving average of $235.25, it highlights a stable performance with a fifty-two-week range from $218.75 to $269.52, illustrating its consistent trading behavior amid market fluctuations.
Investment Potential
Investors should take note of the favorable indicators surrounding BDX, supported by an overall ‘buy’ recommendation from analysts. With 15 analysts contributing to the evaluation, the average recommendation stands at 1.9 on a scale where lower values represent stronger buy signals. The analysis outlines a target low price of $240.00, providing some protection against potential losses. As the stock seeks to regain momentum approaching previous highs, it remains vital for investors to consider these performance metrics and external market dynamics while evaluating their potential strategies with Becton, Dickinson and Company (BDX).
| Metric | Value |
|---|---|
| Market Cap | $67.5b |
| Total Debt | $19.3b |
| Total Cash | $5.3b |
| Shares Outstanding | 289.0m |
| Float Shares | 288.4m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.